Genprex Inc. (NASDAQ: GNPX) maintained upside momentum in yesterdays session, and closed the day with gains of 23.44%. This came after news that, independent researchers had found the companys TUSC2 to be a possible novel biomarker for treating thyroid cancer. The results found that, the overexpression of TUSC2 reduced thyroid cancer tumor metastasis. It was also shown to drive up sensitivity to apoptosis by pushing up cytochrome C and SMAC/DIABLO protein levels.

Thestudy further noted that, there was a high chance that TUSC2 was effective intreating thyroid cancer and that, it adds to research on TUSC2 way beyond thenon-small cell lung cancer treatment that the company was earlier looking into.The independent research was published in the International Journal ofMolecular Sciences.

Theresearchers also concluded that from their studies, TUSC2 has a negativeassociation with the aggressiveness of thyroid cancer. As such, it could be anew target and biomarker for thyroid cancer treatment. They also stated that,thyroid carcinoma is one of the most prevalent endocrine cancers and takesdifferent forms. They further noted that, anaplastic carcinoma is rare, but isone of the most dangerous subtypes.People suffering from it usually exhibit increased neck mass, a high rateof metastases and a 95% mortality at only 6 months. On the other hand,papillary thyroid carcinoma is more common, but has good outcomes and iscurable with radioiodine surgery and surgery.

Commentingon this research, Genprex CEO Rodney Varner stated that, the company isencouraged by the data conducted by different institutions on TUS2 that suggestit is helpful in treating multiple cancers.

Fromits price action, GNPX is in an uptrend. The stock opened the day at $1.57 andtraded between a low of $1.37, and a high of $1.75 before closing the day at$1.75. Volumes in the day stood at 21.44 million.

About GenPrex Inc.

GenPrexInc. is a gene therapy company that develops technologies for people sufferingfrom cancer. It is based in Austin, Texas.

Read the original here:
Genprex Inc. (NASDAQ: GNPX) Up, As Independent Research Reveals TUSC2 Could Be A Therapy For Thyroid Cancer - Invest Million

Comments are closed.